title: Carbohydrate-lipid profile and use of metformin with micronized fenofibrate in reducing metabolic consequences of craniopharyngioma treatment in children: single institution experience.
abstract: OBJECTIVE
  To evaluate auxology and metabolic disturbances in children with craniopharyngioma, and to present observational results of treatment of metabolic sequels with metformin and micronized fenofibrate.
  
  
  METHODS
  The studied group comprised 22 children [median age at diagnosis 10.5 (0.17-16.75) years; median follow-up 5.1 years]. Assessment included height standard deviations (SDS), body mass index (BMI) SDS, concentrations of lipids, glucose and insulin (fasting or oral glucose tolerance test) and homeostatic model assessment of insulin resistance (HOMA-IR) index. Ten adolescents with hyperinsulinemia and dyslipidemia received therapy with metformin (500-1500 mg/daily) and micronized fenofibrate (160 mg/daily).
  
  
  RESULTS
  At diagnosis, median hSDS was -1.66 (range: -4.08; +0.1). Nine (40.9%) children were growth hormone-treated. There was gradual increase of BMI SDS, 18 (81.8%) patients being overweight at the final assessment. Dyslipidaemia was found in 19 patients (86.4%), hyperinsulinaemia in 11 patients (50%) and elevated HOMA-IR in 15 patients (68.2%). Decrease of triglycerides [median 263.5 (171-362) mg/dL vs. 154 (102-183) mg/dL] and HOMA-IR [8.64 (5.08-12.65) vs. 4.68 (0.7-7.9)] was significant in the group treated with metformin and fenofibrate for 6 months.
  
  
  CONCLUSIONS
  Significant auxologic changes and metabolic abnormalities were found in children treated for craniopharyngioma. The use of metformin and fenofibrate seemed to attenuate these disturbances in a short-term observation.
authors.forename: Maria Aleksandra
authors.initials: MA
authors.lastname: Kalina
authors.forename: Marta
authors.initials: M
authors.lastname: Wilczek
authors.forename: Barbara
authors.initials: B
authors.lastname: Kalina-Faska
authors.forename: Eliza
authors.initials: E
authors.lastname: Skała-Zamorowska
authors.forename: Marek
authors.initials: M
authors.lastname: Mandera
authors.forename: Ewa
authors.initials: E
authors.lastname: Małecka Tendera
mesh_terms: D000293:Adolescent; D002241:Carbohydrates / Q000097:blood*; D002648:Child; D002675:Child, Preschool; D003397:Craniopharyngioma / Q000150:complications / Q000188:drug therapy* / Q000453:epidemiology / Q000378:metabolism*; D050171:Dyslipidemias / Q000188:drug therapy / Q000453:epidemiology / Q000209:etiology; D005260:Female; D011345:Fenofibrate / Q000008:administration & dosage*; D005500:Follow-Up Studies; D018149:Glucose Intolerance / Q000188:drug therapy / Q000453:epidemiology / Q000209:etiology; D006801:Humans; D007223:Infant; D007333:Insulin Resistance; D008055:Lipids / Q000097:blood*; D008297:Male; D024821:Metabolic Syndrome / Q000517:prevention & control; D055442:Metabolome; D008687:Metformin / Q000008:administration & dosage*; D010911:Pituitary Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000453:epidemiology / Q000378:metabolism*; D012189:Retrospective Studies
chemical_list: D002241:Carbohydrates; D008055:Lipids; D008687:Metformin; D011345:Fenofibrate